BioSpace News Archive

Genegoggle is unveiling the chromatin physical properties (3D DNA folding) of cells derived from diffuse intrinsic pontine gliomas (DIPG).

EpicentRx, Inc., a clinical stage drug and device company, in collaboration with the Texas Children’s Cancer Center in Houston, today announced the start of a Phase 1 study to examine the safety and benefit of its lead small molecule, RRx-001, plus irinotecan and temozolomide for pediatric patients with recurrent or progressive malignant solid and central nervous system tumors.

PharmaDrug receives encouraging potency data for candidate DMT-analogue molecules designed to treat primary open angle glaucoma

Rising prevalence of chronic and acute diseases worldwide and rapid adoption of clinical decision support systems in healthcare settings are among the key factors driving market revenue growth.

NGMedical, a German medical device manufacturer exclusively focused on creating innovative technologies for spinal applications announces the first USA implantation of its purely additively manufactured titanium BEE® PLIF.

Plasma therapy or convalescent plasma therapy is one of the most popular and constructive methods to boost the immune system.

Pets are now treated as a family member. People opt for pet insurance and proper health care plan and maintain their diet.

The study will evaluate the feasibility of replacing systemic androgen deprivation therapy (ADT) with targeted local delivery of an anti-androgen agent in patients in whom ADT plus radiation therapy is indicated for the treatment of localized prostate cancer.

Maze Therapeutics, today announced the publication in Nature of new findings describing a connection between genetic variation in UNC13A, a gene critical to the function of the nervous system, and the abnormal build-up of TDP-43, a hallmark molecular characteristic of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

Purdue Pharma L.P. announced today that FDA has approved its abbreviated new drug application for Nalmefene hydrochloride injection, 2mg/2mL (1mg/1mL).